Search

Lamisil Tablet樂膚舒

Lamisil Tablet

terbinafine

Manufacturer:

Novartis

Distributor:

DCH Auriga - Healthcare
/
Four Star
Concise Prescribing Info
Contents
Terbinafine HCl
Indications/Uses
Fungal infections of the skin & nails caused by Trichophyton, Microsporum canis & Epidermophyton floccosum. Ring worm (tinea corporis, tinea cruris & tinea pedis) where oral therapy is considered appropriate due to the site, severity or extent of the infection. Onychomycosis.
Click to view Lamisil Tablet detailed prescribing information
Dosage/Direction for Use
Adult 250 mg once daily. Duration of treatment varies according to indication & severity of infection: Tinea pedis (interdigital, plantar/moccasin type) 2-6 wk. Tinea corporis 4 wk. Tinea cruris 2-4 wk. Onychomycosis 6 wk-3 mth.
Click to view Lamisil Tablet detailed prescribing information
Overdosage
View Lamisil Tablet overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Chronic or active hepatic disease.
Click to view Lamisil Tablet detailed prescribing information
Special Precautions
Hepatotoxicity; pre-existing psoriasis; blood dyscrasias; lupus erythematosus; renal impairment (CrCl <50 mL/min). Monitor periodically liver function test (after 4-6 wk of treatment). May affect ability to drive or operate machinery. Pregnancy & lactation.
Click to view Lamisil Tablet detailed prescribing information
Adverse Reactions
Decreased appetite; GI symptoms (feeling of fullness, abdominal distention, dyspepsia, nausea, abdominal pain, diarrhoea); non-serious forms of skin reactions (rash, urticaria); musculoskeletal reactions (arthralgia, myalgia). Headache.
Click to view Lamisil Tablet detailed prescribing information
Drug Interactions
Decreased clearance w/ cimetidine. Increased exposure w/ fluconazole, ketoconazole & amiodarone (CYP2C9 & CYP3A4 inhibitors). Increased clearance w/ rifampicin. Reports of some cases of menstrual disturbance when co-administered w/ OCs. Decreased clearance of caffeine (IV), desipramine & CYP2D6 substrates (eg, TCAs, β-blockers, SSRIs, antiarrhythmics, MAOIs). Increased metabolic ratio of dextromethorphan/dextrorphan in urine. Increase clearance of ciclosporin. Rare cases of changes in INR &/or prothrombin w/ warfarin.
Click to view Lamisil Tablet detailed prescribing information
Description
View Lamisil Tablet description for details of the chemical structure and excipients (inactive components).
Action
View Lamisil Tablet mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Antifungals
ATC Classification
D01BA02 - terbinafine ; Belongs to the class of antifungals for systemic use.
Presentation/Packing
Form
Lamisil Tablet 250 mg
Packing/Price
14's;28's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in